IP Library Granted Patent US 9,919,034
Granted Patent B2
US 9,919,034 · App. 14/736,170 · Granted Mar 20, 2018

Methods of treating and prophylactically protecting mammalian patients infected by viruses classified in Baltimore group V

Inventor: Thomas W. Hodge, III (Athens, GA)
Assignee: TAMIR BIOTECHNOLOGY, INC.
A61K38/465C12N9/22C12Y301/27C12Y301/27005A01N63/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,919,034
App. No.
14/736,170
Granted
Mar 20, 2018
Kind
B2
Abstract

Viral infections in mammals can be treated and prophylactically prevented by systemic administration of ranpirnase and three other ribonucleases that are highly homologous with it and that have activities that are highly similar to it. Experimental results against rabies, Middle East Respiratory Syndrome Coronavirus (“MERS-CoV”), influenza, Ebola virus, Chikungunya virus, Venezuelan equine encephalitis, canine parvovirus, adenovirus-2, respiratory syncytial virus, rhinovirus-14, and vaccinia are disclosed.

Claims (15)

1. A method of treating a viral infection in a mammalian patient, the viral infection being classified in Baltimore Classification Group V, comprising systemically administering a therapeutically effective dose of a therapeutic agent to the patient, wherein the therapeutic agent consists of ranpiranse.

2. A method of treating a rabies infection in a mammalian patient, comprising systemically administering a therapeutically effective dose of a therapeutic agent to the patient, wherein the therapeutic agent consists of ranpirnase.

3. The method of claim 1 or 2 , wherein the patient is a human being.

4. A method of prophylactically protecting a patient from:

a. rabies; or

b. influenza; or

c. respiratory syncytial virus; or,

d. Ebola virus,

comprising the step of administering a therapeutically effective dose of ranpirnase to the patient.

5. A method of treating an Ebola infection in a mammalian patient, comprising systemically administering a therapeutically effective dose of ranpirnase to the patient.

6. A method of treating a respiratory syncytial infection in a mammalian patient, comprising systemically administering a therapeutically effective dose of a therapeutic agent to the patient, wherein the therapeutic agent consists of ranpirnase.

7. A method of prophylactically protecting a mammalian patient from a viral infection classified in Baltimore Classification Group V, comprising systemically administering a therapeutically effective dose of ranpirnase to the patient.

8. The method of claim 4 , 5 , 6 , or 7 , wherein the patient is a human being.

9. The method of claim 1 , wherein the viral infection is an influenza infection.

10. The method of claim 1 , wherein the viral infection is a measles infection.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 12, 2026
From: ORGENESIS, INC
To: OKOGEN, INC
Reel/Frame 074059/0717 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 25, 2026
From: ORGENESIS INC.
To: OKOGEN, INC.
Reel/Frame 073890/0884 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 10, 2020
From: TAMIR BIOTECHNOLOGY, INC.
To: ORGENESIS INC.
Reel/Frame 052892/0702 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 10, 2015
From: HODGE, THOMAS W., III, DR.
To: TAMIR BIOTECHNOLOGY, INC.
Reel/Frame 035819/0313 →
Continuity (9)
Continuation In Part 14667282 · Mar 24, 2015
Continuation In Part 14316893 · Jun 27, 2014
Continuation In Part 14247723 · Apr 8, 2014
Continuation In Part 14229816 · Mar 28, 2014
Provisional Application 62147209 · Apr 14, 2015
Provisional Application 62102671 · Jan 13, 2015
Provisional Application 62063551 · Oct 14, 2014
Provisional Application 62040885 · Aug 22, 2014
Related Publication 20150376584A1 · Dec 31, 2015